Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568546 | 1.00 | KDM4E (0.80) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6274286 | 1.00 | KDM4E (0.80) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6243641 | 0.91 | KDM4E (0.88) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6243643 | 0.91 | KDM4E (0.88) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6274622 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6274619 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29440105 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5563916 | 0.89 | KDM4E (0.74) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5568508 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6244780 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | INSERM | 2003-02-06 | — | — | US | disclosed |
| US-6403561-B1 | DISORDERS ASSOCIATED WITH THE INACTIVATION OR EXCESSIVE DEGRADATION OF CHOLECYSTOKININ; INHIBITING THE ENZYMATIC HYDROLYSIS OF CHOLECYSTOKININ 1-(2(S)-AMINOBUTYRYL)-2(S)-INDOLINECARBOXYLIC ACID | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027743-A1 | Tripeptidylpeptidase inhibitors | DPP4, DPP3, DPP9 | KDM4E 3475/4885ALDH1A1 630/4885CYP1A2 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.